Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Alexander Edward Dela Cruz Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan et al. · New England Journal of Medicine · 2020
BACKGROUND: fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown. METHODS: fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety. RESULTS: fusion-positive NSCLC who had previously received at least platinum-based chemotherapy, the percentage with an objective response was 64% (95% confidence interval [CI], 54 to 73). The median duration of response was 17.5 months (95% CI, 12.0 to could not be evaluated), and 63% of the responses were ongoing at a median follow-up of 12.1 months. Among 39 previously untreated patients, the percentage with an objective response was 85% (95% CI, 70 to 94), and 90% of the responses were ongoing at 6 months. Among 11 patients with measurable central nervous system metastasis at enrollment, the percentage with an objective intracranial response was 91% (95% CI, 59 to 100). The most common adverse events of grade 3 or higher were hypertension (in 14% of the patients), an increased alanine aminotransferase level (in 12%), an increased aspartate aminotransferase level (in 10%), hyponatremia (in 6%), and lymphopenia (in 6%). A total of 12 of 531 patients (2%) discontinued selpercatinib because of a drug-related adverse event. CONCLUSIONS: fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).
Cited by 828 works. doi:10.1056/nejmoa2005653 Open-access PDF
Authors
- Alexander Edward Dela Cruz Drilon
- Geoffrey R. Oxnard
- Daniel Shao-Weng Tan
- Herbert Ho-Fung Loong
- Melissa Lynne Johnson
- Justin F. Gainor
- Caroline Elizabeth McCoach
- Oliver Pascal Gautschi
- Benjamin Besse
- Byoung Chul Cho
- Nir Peled
- Jared M. Weiss
- Yu-Jung Kim
- Yuichiro Ohe
- Makoto Nishio
- Keunchil Park
- Jyoti D. Patel
- Takashi Seto
- Tomohiro Sakamoto
- Ezra Y. Rosen
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- The National Comprehensive Cancer Network
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
- Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial